Commonwealth Retirement Investments LLC Buys 2,792 Shares of Johnson & Johnson (NYSE:JNJ)

Commonwealth Retirement Investments LLC grew its stake in shares of Johnson & Johnson (NYSE:JNJ) by 8.6% in the 4th quarter, HoldingsChannel reports. The fund owned 35,193 shares of the company’s stock after purchasing an additional 2,792 shares during the quarter. Johnson & Johnson makes up 2.9% of Commonwealth Retirement Investments LLC’s investment portfolio, making the stock its 10th largest position. Commonwealth Retirement Investments LLC’s holdings in Johnson & Johnson were worth $5,516,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently made changes to their positions in JNJ. Hibernia Wealth Partners LLC bought a new position in Johnson & Johnson during the third quarter worth about $27,000. FNY Investment Advisers LLC acquired a new position in shares of Johnson & Johnson during the 3rd quarter worth approximately $37,000. Tower View Wealth Management LLC increased its holdings in shares of Johnson & Johnson by 183.3% during the third quarter. Tower View Wealth Management LLC now owns 255 shares of the company’s stock worth $40,000 after purchasing an additional 165 shares during the period. Creative Capital Management Investments LLC raised its position in shares of Johnson & Johnson by 43.0% in the third quarter. Creative Capital Management Investments LLC now owns 286 shares of the company’s stock valued at $45,000 after buying an additional 86 shares in the last quarter. Finally, VitalStone Financial LLC bought a new stake in shares of Johnson & Johnson in the second quarter valued at approximately $48,000. Institutional investors own 69.55% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have weighed in on JNJ shares. Raymond James lifted their price objective on Johnson & Johnson from $172.00 to $175.00 and gave the company an “outperform” rating in a report on Wednesday, January 3rd. Wells Fargo & Company downgraded Johnson & Johnson from an “overweight” rating to an “equal weight” rating and dropped their price target for the company from $170.00 to $163.00 in a research note on Wednesday, December 13th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, February 6th. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a report on Wednesday, March 13th. Finally, Morgan Stanley cut their price target on shares of Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating for the company in a report on Wednesday, January 24th. Seven equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average target price of $177.31.

Insider Buying and Selling

In other Johnson & Johnson news, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $25.81, for a total value of $96,142.25. Following the completion of the transaction, the insider now directly owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other Johnson & Johnson news, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the sale, the insider now owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Jennifer L. Taubert sold 59,397 shares of the firm’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $156.27, for a total value of $9,281,969.19. Following the sale, the executive vice president now directly owns 141,416 shares of the company’s stock, valued at approximately $22,099,078.32. The disclosure for this sale can be found here. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Stock Up 0.5 %

Shares of NYSE:JNJ opened at $152.31 on Wednesday. Johnson & Johnson has a 52-week low of $144.95 and a 52-week high of $175.97. The company has a market capitalization of $367.03 billion, a PE ratio of 11.03, a price-to-earnings-growth ratio of 2.56 and a beta of 0.53. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.91 and a current ratio of 1.16. The company has a fifty day moving average of $157.79 and a 200-day moving average of $156.18.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, January 23rd. The company reported $2.29 EPS for the quarter, beating the consensus estimate of $2.28 by $0.01. The firm had revenue of $21.40 billion during the quarter, compared to the consensus estimate of $21.02 billion. Johnson & Johnson had a return on equity of 37.27% and a net margin of 37.79%. The business’s quarterly revenue was down 9.7% on a year-over-year basis. During the same period last year, the company earned $2.35 earnings per share. On average, equities analysts predict that Johnson & Johnson will post 10.65 EPS for the current fiscal year.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.